Clinical Trials Directory

Trials / Unknown

UnknownNCT01420185

Identification of Genes That Predict Local Recurrence in Samples From Patients With Breast Cancer Treated on NSABP-B-28

Molecular Predictors of Loco-Regional Recurrence in Node Positive Breast Cancer

Status
Unknown
Phase
Study type
Observational
Enrollment
1,300 (estimated)
Sponsor
NSABP Foundation Inc · Network
Sex
Female
Age
18 Years – 78 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict whether cancer will come back after treatment. PURPOSE: This research trial is studying genes that may predict local recurrence in samples from patients with breast cancer. treated on NSABP-B-28

Detailed description

OBJECTIVES: * To evaluate the association between the 21-gene Recurrence Score and risk of local-regional recurrence (LRR) in node-positive, estrogen receptor- (ER) positive (+) patients treated with cyclophosphamide and doxorubicin hydrochloride (AC) with or without paclitaxel in the NSABP-B-28 trial. * To evaluate the potential for combining the 21-gene Recurrence Score (RS) with traditional clinico-pathologic factors in order to derive an improved algorithm for prediction of LRR risk and in order to identify subgroups of ER-positive patients with 1-3 or 4 or more positive nodes who do/do not need post mastectomy chest wall radiotherapy (XRT) or regional nodal XRT (irrespective of surgical procedure). * To evaluate whether the 21-gene RS predicts benefit from adding paclitaxel to AC chemotherapy in reducing risk of LRR, and improving disease-free survival (DFS) and overall survival (OS) in node-positive, ER-positive patients from NSABP-B-28. OUTLINE: RNA extracted from paraffin-embedded tissue samples are analyzed for gene expression profile by Ribogreen assay and RT-PCR. Results are then compared and analyzed with each patient clinical-pathologic factors, including tumor size, patient age, number of positive nodes (1-3, 4+), tumor grade, and surgery type (mastectomy or lumpectomy).

Conditions

Interventions

TypeNameDescription
GENETICRNA analysis
GENETICgene expression analysis
GENETICmicroarray analysis
GENETICreverse transcriptase-polymerase chain reaction
OTHERlaboratory biomarker analysis

Timeline

Start date
2011-10-01
Primary completion
2015-12-01
First posted
2011-08-19
Last updated
2015-05-08

Source: ClinicalTrials.gov record NCT01420185. Inclusion in this directory is not an endorsement.